Clinical trials
Kidney Transplant Rejection clinical trials
Below are recruiting kidney transplant rejection clinical trials, each written for real people, not researchers. We’re tracking 80 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06830473Recruiting
Study on predicting kidney transplant rejection in Scotland
This study looks at whether certain tests can help predict or diagnose kidney transplant rejection. If you have had a kidney transplant and are being followed at a main transplant centre in Scotland, you may be able to take part by giving urine samples during your regular check-ups.
EdinburghAges 18–99 - NCT06825117Enrolling by invitation
Probiotics after kidney transplant
This trial tests whether taking a probiotic supplement helps people recovering from a kidney transplant. If you are between 18 and 75 years old and had a smooth recovery in the first month after surgery, you may be able to join.
UdineAges 18–75 - NCT06801886Enrolling by invitationPhase 3
Silymarin for better kidney transplant success
This trial tests if adding silymarin (a milk thistle extract) to standard anti-rejection medicines helps protect the new kidney from damage. It may improve how well the transplanted kidney works over time.
MartinAges Any age - NCT06474273RecruitingPhase 3
Treating acute rejection after a kidney or kidney-pancreas transplant
This study compares two ways of treating acute rejection (when the immune system attacks the new organ) in people who have had a kidney or combined kidney-pancreas transplant. It looks at whether adding a different approach helps protect the transplant long-term.
Lambton, New South WalesAges 2 years+ - NCT06365411Enrolling by invitation
Genomic medicine study for kidney transplant patients
This study looks at the genes of people who have had or will have a kidney transplant. It aims to learn how genetic information might help improve transplant care over time. Participants will give blood, urine, stool, and possibly kidney tissue samples for research.
Westmead, New South WalesAges 18–80 - NCT06351488Recruiting
Detecting kidney DNA to spot organ rejection early
This study looks for pieces of kidney DNA in the blood of people who have a kidney transplant and need a biopsy. The goal is to see if this test can help doctors know if the kidney is being rejected without needing a biopsy.
ParisAges 18 years+ - NCT06126380Enrolling by invitationPhase 2
Long-term safety of tegoprubart in kidney transplant patients
This is a long-term follow-up study for people who have already completed a study of the drug tegoprubart after a kidney transplant. It checks how safe and effective the drug is over a longer period.
Los Angeles, CaliforniaAges 18–100 - NCT06013865RecruitingPhase 4
Empagliflozin for kidney transplant recipients
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
Hines, IllinoisAges 19 years+ - NCT05917522RecruitingPhase 2
Biomarker-guided changes to anti-rejection medicines after kidney transplant
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
Birmingham, AlabamaAges 18–70 - NCT05525507RecruitingPhase 1
Test early immune-tolerance treatment for matched kidney transplant patients
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Los Angeles, CaliforniaAges 18 years+ - NCT05325008RecruitingPhase 3
IVIG treatment for BK virus after kidney transplant
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Canberra, Australian Capital TerritoryAges 2 years+ - NCT05285878Enrolling by invitationPhase 2
Fingolimod to protect kidney function after kidney transplant
This trial tests whether fingolimod can reduce kidney scarring and preserve kidney function after a new kidney transplant. It focuses on people who are in the early period after transplant who may be at risk for scarring in the kidney.
Houston, TexasAges 18–65 - NCT05084768Recruiting
Test blood markers to predict kidney transplant rejection
This study looks at special blood tests to help predict when kidney transplant rejection might happen. If the markers work, they could help doctors catch rejection earlier and adjust treatment sooner.
Loma Linda, CaliforniaAges 18 years+ - NCT04870437Recruiting
Light therapy study for kidney transplant rejection immune cells
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
BesançonAges 18 years+ - NCT03707262RecruitingPhase 1/Phase 2
Brother or sister donor transplant using kidney and stem cells
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Los Angeles, CaliforniaAges 18 years+ - NCT01531257Recruiting
Monitoring genes and health after kidney transplant
This study follows people who are getting a kidney transplant (first or later) to better understand how the body recovers, using health tracking and “gene/protein” (proteogenomic) information. It may help doctors predict complications and improve care after transplant.
Chicago, IllinoisAges 18 years+ - NCT05015231Recruiting
MRI study after fistula closure in kidney transplant patients
This trial uses special MRI scans to see how blood flow in the transplanted kidney changes after your fistula is surgically closed. It may help doctors better understand what healthy recovery looks like after the procedure.
ZurichAges 18 years+ - NCT07870811Recruiting
Wellness program to improve quality of life after organ transplant
This study tests a program of exercise, education, and other non-drug activities to help people who have had an organ transplant feel better and improve their daily lives. It is for people who are at least one year past their transplant and have some quality-of-life concerns.
Palermo, PalermoAges 25–65 - NCT07539857RecruitingPhase 2
Belimumab to help highly sensitized kidney transplant candidates
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
LeidenAges 18 years+ - NCT07508787RecruitingPhase 2
Study comparing siplizumab to another drug for kidney transplant acceptance
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Sacramento, CaliforniaAges 18–70 - NCT07370727Recruiting
Weight training for kidney transplant patients
This trial studies whether a personalized weight training program helps kidney transplant recipients improve their strength and health. It is for people who are at least one year post-transplant and have stable kidney function.
Bogotá, Bogota D.C.Ages 18–50 - NCT06751992RecruitingPhase 4
Thinking and memory with extended-release tacrolimus in kidney transplant
This study tests if switching to an extended-release form of your anti-rejection medication (tacrolimus) helps protect memory and thinking skills. It is for older adults who have had a kidney transplant at least one year ago.
Boston, MassachusettsAges 65 years+ - NCT04239703Recruiting
Kidney transplant biopsy study using blood test clues
This study looks at kidney transplant patients who are getting a kidney biopsy for usual clinical reasons. It tests whether special blood test results (from a sample taken as part of the study) can help spot transplant kidney problems earlier or more accurately.
Tampa, FloridaAges Any age - NCT04450953RecruitingPhase 3
Eplerenone to slow blood vessel damage after kidney transplant
This trial tests whether eplerenone can slow the progression of blood vessel (vasculature) problems in people who have had a kidney transplant. You may be eligible if you are older, stable on your transplant medicines, and have higher peripheral artery blood pressure readings.
Vandœuvre-lès-NancyAges 50 years+
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for kidney transplant rejection?
- Yes. Clin2 currently lists 80 recruiting kidney transplant rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kidney transplant rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kidney transplant rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.